We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
08/1/2023 21:14 | Yes very surprising but how long have they been manipulating the price down ......not complaining, let's enjoy ;) | richpassi | |
08/1/2023 21:11 | Well, that's an unexpected treat on a Sunday night! | iamnotanumber6 | |
08/1/2023 21:10 | I'll be happy to see the back of Nasdaq, but need to work out where on the old LSE chart the announced value puts us. Obviously seems good to where it has been for a long while ;) I needed a way out but didn't want to sell so low and lose out on exchange rate .......we need Liz and kwasi back in to sort out the dollar/pound rate until we get paid out !!! Lol | richpassi | |
08/1/2023 21:04 | All those long-suffering shareholders finally got a payday! | whatno | |
08/1/2023 20:49 | Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved - Total Transaction value of up to US$1.48 Billion with upfront consideration representing a 107% premium to Amryt ADS’ closing price on January 6, 2023 | bermudashorts | |
17/11/2022 17:59 | Cheers for that dcme doesn't paint the prettiest of pictures for Amryt :( | richpassi | |
16/11/2022 13:35 | Some interesting info in this article about pricing and competition. hXXps://www.evaluate | dcme | |
08/11/2022 14:37 | Looks like they haven't even started the dispute resolution process with the FDA. Also, the buyback plan seems to be going at a snails pace and is having no effect on the stock price which just continues to drift/drop. | dcme | |
25/10/2022 14:48 | Can't understand why they are listed on NASDAQ as there seems to be no interest in the stock. They probably figured that FDA approval for Filsuvez would generate some US institutional interest. Sadly the FDA didn't buy the trial results. | dcme | |
24/10/2022 06:53 | More to the point did YOU get them ? Lol Got mine about 3 weeks ago from Halifax but it was only a little compensation from where we were to where we are now :( Will Amryt ever be accepted by the US.Was Nasdaq the boards method of killing the share price to be able to buy back for for Dimes ! | richpassi | |
17/10/2022 14:20 | Broker got my funds from AMYT last week. | punter6 | |
04/10/2022 11:21 | Broker says that funds being sent to them by cheque so will take time to clear!!! | punter6 | |
28/9/2022 15:44 | Just checked my account again and shown as credited on 22 January but as umgowah mentioned, I got no reply to my message and no notification that they had been redeemed! | pj84 | |
26/9/2022 16:32 | Yes me too. | bermudashorts | |
26/9/2022 16:03 | Finally got credit via HL. | waterloo01 | |
21/9/2022 15:49 | I seem to remember that HL were also very slow crediting the CVRs to my account in the first place. | bermudashorts | |
21/9/2022 15:19 | I messaged them a month ago regarding removing the FDA CVR - no reply. I messaged them a week ago regarding the EMA payment date. Still no reply. I phoned them this morning, and "the Corporate Actions Team are very busy" but someone will get back to me. Unfortunately HL are but a shadow of their pre wfh days. | umgowah | |
20/9/2022 23:46 | Still no information from HL on the process for CVR's held in nominee accounts, so I have messaged them to get an update. | pj84 | |
18/9/2022 19:33 | waterloo01 I am also with HL and nothing in my account maybe some time next week? | pj84 | |
16/9/2022 19:02 | AJ Bell added this to their corporate actions yesterday sometime... Amryt Pharma has announced that the European Medicines Agency (EMA) Contingent Value Rights (“CVRs”) which were issued to shareholders following completion of the scheme of arrangement on 25 September 2022 will now become payable. Under the terms of the redemption, you will be issued with one loan note of USD0.0995 for each CVR you hold. Please note, the loan notes will not be credited to your account. The loan notes will be redeemed in full on or around 14 September 2022. Your account will be credited with USD0.0995 for each loan note that is redeemed. So as Punter6 said; it's a few bob. :) | exfm | |
15/9/2022 18:28 | Not heard anything from HL? | waterloo01 | |
15/9/2022 15:23 | I contacted my Broker yesterday,as it was the designated payment date,and he checked it out and told me I'd be getting c.$3,000 so he's diaried it on for 3 weeks' time to follow up for me. In fairness,he's a sound guy. (I'm with Cantor Fitzgerald in Dublin) | punter6 | |
14/9/2022 16:44 | I posted back about 3 months ago and I think it was 9.95 us cents per CVR. Is this what you have received? It was meant to be the 14th Sept.I am with AJ Bell and have not heard anything as of yet. | exfm | |
14/9/2022 16:22 | The broker confirmed I will be getting a few bob for the CVR's after all. Better than nothing. | punter6 | |
09/9/2022 06:37 | Interest dropped off the cliff as soon as Amryt went totally Nasdaq, even when they first listed on Nasdaq, the people across the pond always had a downer on it. There doesn't seem to be any places to converse about the company apart from here occasionally. It's obvious we are a very small group of original holders suffering in silence. | richpassi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions